Monday, December 4, 2023

Draconian Pharma

Draconian Pharma

   I live by the grace of a drug marketed by AbbVie Pharmaceuticals.  You and your children will die by their hands.  The vehicle that will be your demise is called greed.  It is the driving force behind many other drug companies as well.  Here is my and your story.  I told the story in a previous blog, Golden Goose Economics, but I employed satire to tell the tale.  Satire is a language not understood by some, so here is the threat without satire.

   In 2009 my annual blood tests showed that I had CLL (Chronic Lymphocytic Leukemia) a deadly malignancy.  It remained in the “wait and see” stage until in 2019 the lymphocyte count went up to stage three.  At that time my oncologist recommended a drug called Imbruvica (the generic name is Ibrutinib) at a cost to Medicare of 195 thousand dollars/year/patient.  It required that I pay a three thousand dollar a month copay.  I don’t have three thousand dollars a month over and above my living costs.  So, I turned the offer to extend my life down.

   Soon after my turn down I received a call from a foundation ready to pay my required copay.  The young woman asked me what my annual income was, and then said that I had qualified for the assistance.  I have applied for many financial programs in my life and have never had one approved without income verification.  This fact prompted me to ask, “Who funds this foundation?”  She confirmed my suspicions by answering, “The Pharmaceutical Manufacturers.”  I understood that the Pharmaceutical (AbbVie) had priced the drug so high that the bulk of the potential patients could not afford the copay.  And, they would receive their donation back from the foundation when the copay was returned.  This draconian plan was probably engineered by Richard Gonzales, CEO of AbbVie.  The CLL organization estimates that there are presently, approximately two hundred thousand Medicare patients with CLL.  With this number of clients AbbVie would recover its investment of twenty one billion dollars for the patent rights of Ibrutinib in about a year and a half.  This is an excellent return on investment and spells out the end of Medicare.  There are other pharmaceuticals joining the program.  The financial success is no secret among them.

   Who is to blame for this egregious future ending of Medicare?  Let’s start at the bottom.  I am.  I am willing to participate in this scam so that I may live longer.  Next up, my oncologist.  They do not prescribe the drug without knowledge of the preceding events.  They could try to change it with their powerful AMA lobbyists.  But, in the short run, if they like being willfully blind, the drug offers effective patient care.  Next up, the pharmaceuticals and their lobbyists, they fully understand the game.  The CEOs like Gonzales are so infected with greed (the malignant form of self-preservation) that they are willing to sacrifice the lives of their children and their children’s children.  At the top of the corruption are your elected representatives.  They are the folks that create and enforce patent rights.  You elected them to serve the people, not the soulless wealth of the nation.

   What are patent rights?  They are designed to protect the rights of the creator of a desirable product and to reward the toil of a creator.  When Celera Pharmaceutical sold Ibrutinib to Pharmacyclics for three million dollars it was probably for a fair profit and to a company capable of logistics required to produce and distribute the product.  Then Johnson & Johnson paid Pharmacyclics for its patent rights $975 million.  Are you starting to smell a foul odor?  The next transaction has AbbVie paying $21 billion for these patent rights.  A billion is a thousand millions.  Twenty-one of them is going to result in a very high price for a lifesaving drug.  Are we dealing with greed now or protecting an inventor?  The purpose of any law is a shield for those in need of protection, not a sword for the greedy.  A well written patent law would protect the creator and perhaps a distributer with the purchase at perhaps 15% over the book value of the company, but no protection to a third purchaser.  This would be fair and effective.  With the large dollar influence on those who govern us, fair and effective is rare.

Cheers, Old Buz                   December 4th, 2023

Remember:

One cannot fool all of the people all of the time … and that is why we have two political parties.” - Anon                                                                                                                                             

No comments:

Post a Comment